January 14, 2020
Tokyo-based biotech Healios has said that it has added its cancer immunotherapy HLCN061, being developed by employing allogeneic iPS cell-derived natural killer cells, to its development pipelines. HLCN061, discovered and developed by the company, is a next generation immunotherapy being...read more